试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Grazoprevir (MK-5172) With Peg-Interferon and Ribavirin in Participants With Chronic Genotype 2 or 3 Hepatitis C (MK-5172-012)
编号:NCT01440595登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:Grazoprevir、Placebo to Grazoprevir、Peginterferon alfa-2b (Peg-IFN)、Ribavirin (RBV)
登记的停止原因(原文):Preliminary results of MK-5172 PN003 (NCT01353911) suggested a possible dose relationship to elevated transaminase levels in treatment with grazoprevir.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Testosterone TRANSdermal Gel for Poor Ovarian Responders Trial
编号:NCT02418572登记状态:提前终止企业 / 申办者:Fundacion Dexeus
药物 / 成分:Testosterone gel、Placebo gel
登记的停止原因(原文):Having reached the sample size described for the interim analysis and having seen the post-interim results, the sponsor has decided to stop the trial due to futility.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Efficacy and Safety of Grazoprevir (+) Uprifosbuvir (+) Ruzasvir (MK-3682B) (MK-5172 + MK-3682 + MK-8408) Fixed Dose Combination in Chronic HCV Participants Failing Prior Antiviral Treatment (MK-3682-021)
编号:NCT02613403登记状态:提前终止企业 / 申办者:Merck Sharp & Dohme LLC
药物 / 成分:MK-3682B、Ribavirin
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Safety and Efficacy Study of TNX-102 SL in Patients With Military-related PTSD
编号:NCT03062540登记状态:提前终止企业 / 申办者:Tonix Pharmaceuticals, Inc.
药物 / 成分:TNX-102 SL、Placebo SL Tablet
登记的停止原因(原文):Stopped early due to inadequate separation on primary efficacy endpoint at Week 12 according to Interim Analysis conducted on the first 274 (50%) patients.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy
编号:NCT03387098登记状态:提前终止企业 / 申办者:ImmunityBio, Inc.
药物 / 成分:Aldoxorubicin HCl、ALT-803、ETBX-011、GI-4000
登记的停止原因(原文):Study halted prematurely and will not resume; participants are no longer being examined or receiving intervention
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Study to Evaluate the Efficacy and Safety of HepaStem in Patients With Acute on Chronic Liver Failure (ACLF)
编号:NCT04229901登记状态:提前终止企业 / 申办者:Cellaion SA
药物 / 成分:HepaStem、Placebo
登记的停止原因(原文):Sponsor decision
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Efficacy and Safety Study of BDB-001 in Severe COVID-19 With ALI/ARDS
编号:NCT04449588登记状态:提前终止企业 / 申办者:Staidson (Beijing) Biopharmaceuticals Co., Ltd
药物 / 成分:BDB-001 Injection、Conventional treatment
登记的停止原因(原文):Due to the COVID-19 epidemic situation, the sponsor has decided to terminate the project.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Study of PD-1 Inhibitor JTX-4014 Alone and in Combination With Vopratelimab in Biomarker-selected Subjects With Metastatic NSCLC After One Prior Platinum-containing Regimen
编号:NCT04549025登记状态:提前终止企业 / 申办者:Jounce Therapeutics, Inc.
药物 / 成分:Pimivalimab、Vopratelimab
登记的停止原因(原文):The Sponsor decided to discontinue development of pimivalimab prior to the planned study completion. At the time of the decision to discontinue development, enrollment in the study had been completed.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Oral Iron Frequency for Childhood Restless Leg Syndrome/Periodic Limb Movement Disorder
编号:NCT04610827登记状态:提前终止企业 / 申办者:Mayo Clinic
药物 / 成分:Ferrous sulfate
登记的停止原因(原文):Change in personnel and lack of resources to continue.
查看官方原始记录 ↗试验终止ClinicalTrials.gov(美国登记平台)来源日期:2024-05-22
Efficacy and Safety of Evinacumab in Adult Patients With Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis
编号:NCT04863014登记状态:提前终止企业 / 申办者:Regeneron Pharmaceuticals
药物 / 成分:evinacumab、Placebo
登记的停止原因(原文):Sponsor Decision
查看官方原始记录 ↗